Oncotarget

Reviews:

The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

Pascale A. Cohen _, Caterina F. Donini, Nhan T. Nguyen, Hubert Lincet and Julie A. Vendrell

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:41566-41581. https://doi.org/10.18632/oncotarget.5893

Metrics: PDF 2271 views  |   HTML 3141 views  |   ?  


Abstract

Pascale A. Cohen1,2,3, Caterina F. Donini1,2,3, Nhan T. Nguyen1,2,3, Hubert Lincet1,2,3 and Julie A. Vendrell1,2,3

1 ISPB, Faculté de Pharmacie, Lyon, France

2 Université Lyon 1, Lyon, France

3 INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France

Correspondence to:

Pascale A. Cohen, email:

Keywords: ZNF217, oncogene, biomarker, hallmarks of cancer, carcinogenesis

Received: August 03, 2015 Accepted: September 18, 2015 Published: September 29, 2015

Abstract

The recently described oncogene ZNF217 belongs to a chromosomal region that is frequently amplified in human cancers. Recent findings have revealed that alternative mechanisms such as epigenetic regulation also govern the expression of the encoded ZNF217 protein. Newly discovered molecular functions of ZNF217 indicate that it orchestrates complex intracellular circuits as a new key regulator of tumorigenesis. In this review, we focus on recent research on ZNF217-driven molecular functions in human cancers, revisiting major hallmarks of cancer and highlighting the downstream molecular targets and signaling pathways of ZNF217. We also discuss the exciting translational medicine investigating ZNF217 expression levels as a new powerful biomarker, and ZNF217 as a candidate target for future anti-cancer therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5893